A61K 40/4239
Cell cycle regulated proteins
Official title: {Cell cycle regulated proteins, e.g. cyclin, CDC, CDK or INK-CCR}
A61K40/4239 (Cell cycle regulated proteins) appears on 22 US grants and 39 published applications in this corpus.
Search patents in A61K- Granted patents
- 22
- Published applications
- 39
- Assignees
- 32
- Inventors
- 67
- Latest grant
- 10 Mar 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2003 | 0 | 1 |
| 2004 | 0 | 0 |
| 2005 | 0 | 1 |
| 2006 | 0 | 4 |
| 2007 | 0 | 0 |
| 2008 | 0 | 0 |
| 2009 | 0 | 0 |
| 2010 | 1 | 2 |
| 2011 | 0 | 2 |
| 2012 | 2 | 0 |
| 2013 | 1 | 0 |
| 2014 | 0 | 2 |
| 2015 | 1 | 3 |
| 2016 | 1 | 1 |
| 2017 | 3 | 1 |
| 2018 | 1 | 1 |
| 2019 | 2 | 2 |
| 2020 | 0 | 3 |
| 2021 | 2 | 4 |
| 2022 | 3 | 4 |
| 2023 | 0 | 4 |
| 2024 | 1 | 3 |
| 2025 | 2 | 1 |
| 2026 | 2 | 0 |
By publication year. 2026 runs to 8 Oct.
Recent patents
- Cyclin A1 specific T cell receptors and uses thereof10 Mar 2026US 12,570,712 B2Fred Hutchinson Cancer Center
- T cell receptors and methods of use thereof10 Mar 2026US 12,570,715 B2University Health Network
- Methods of obtaining tumor-specific T cell receptors15 Jul 2025US 12,358,967 B2Hryz (Guangzhou) Biotech Co.
- CDCA1-derived peptide and vaccine containing same14 Jan 2025US 12,195,559 B2Oncotherapy Science, Inc.
- Chimeric antigen receptor (CAR) that targets chemokine receptor CCR4 and its use28 May 2024US 11,992,519 B2The United States Government as represented by the Department of Veterans Affairs
- Borealin targeting polypeptides for detection and treatment of cancer24 Apr 2025US 2025/0127814 A1The University of Chicago
- Methods to determine treatment efficacy with gamma-delta t cells20 Jun 2024US 2024/0197876 A1The Trustees of the University of Pennsylvania
- Methods of obtaining tumor-specific t cell receptors15 Feb 2024US 2024/0052010 A1Hryz Biotech Co.
- Kshv oncoprotein antigens and epitopes for expanding antigen-specific t cells4 Jan 2024US 2024/0000936 A1Children's National Medical Center
- T cells and chimeric stimulating receptors and uses thereof21 Sep 2023US 2023/0293687 A1Eureka Therapeutics, Inc.
Most cited
By later US patents
- Anticancer vaccine and diagnostic methods and reagents5US 7,704,507 B2University of Pittsburgh—Of the Commonwealth System of Higher Education · 2010
- Semi-allogenic anti-tumour vaccine with HLA haplo-identical antigen-presenting cells5US 8,206,701 B2Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) · 2012
- Methods of cancer treatment using tumor antigen-specific T cells3US 11,219,676 B2HRYZ (Shenzhen) Biotech Co. · 2022
- Methods of obtaining tumor-specific T cell receptors3US 11,390,659 B2HRYZ (Shenzhen) Biotech Co. · 2022
- Methods of cancer treatment using tumor antigen-specific T cells2US 11,471,519 B2HRYZ (Shenzhen) Biotech Co. · 2022